October 2026 Random Ramblings
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.
The VMS thesis: "AI is actually a tailwind" "I think most people -this is not a fact in dispute that AI is TAM expanding for software. The debate is who's going to be the claim that TAM expansion. We have a strong thesis that incumbents have a high, high, high right to win." $ROP
"I've never been more excited than I have in my career about the opportunity in front of us with AI. We are literally delivering a button when you press it magic happens. And I've always been in like the boring part of software and all of a sudden, software is not boring." $ROP https://t.co/AIQZYxhy8R
"Product velocity through agentic use cases has increased. We're going through a massive amount of commercial learnings right now. Agentic AI products are hitting the market... The surface area software has just expanded massively because of AI." - $ROP (Citi 2026 TMT)
"We have a business in pharmacy automation. Every prescription today has to be manually verified by a pharmacist today, it costs $1-$2. Our first agentic tool does that at a quality level that's higher than a human and we charge about $0.30. So very tangible ROI from day 1." $ROP
$ROP CFO on private equity being under pressure to return capital showing up in 2027. https://t.co/Xsd1BdKlNc
Correct. $BN https://t.co/3Fa4m1qPxg
First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…
Howmet Aerospace is framed as a beneficiary of turbine and aircraft-engine demand, while J.B.
Palantir is cut to Hold after a 35% multiple-driven rally, while C3.ai is rated Sell on stalled revenue, expensive valuation and weak…
Lennar cut build times to 116 days and adopted an asset-light land model, while gross margin fell to 15.8% from 27.5% as land costs rose.
Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…
Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.
Eaton’s backlog, data-center, grid and aerospace demand, plus a 450–500 bp H2 2026 Electrical Americas margin recovery, support the growth…
Asian insider buying rose 19% to US$2.4 billion across 930 September transactions, led by Grab CEO Anthony Tan’s US$30 million purchase…
ASML’s strong quarterly results failed to prevent a selloff, as AI investors focused on scarcity fears facing chip-equipment makers…
Corning’s NVIDIA-backed 10x fiber expansion, enterprise connector demand and carrier capacity plans frame its optical communications…
WDC · long Western Digital, a hard-disk manufacturer, is pitched as a long after significant share-price moves deter investors.
Verisure’s 6.38 million monitored-alarm subscribers generate 90% recurring revenue, while its disclosed acquisition costs and 6%-8% churn…
BridgeBio Pharma reported Q2 revenue of $243.7 million and has three Priority Review NDAs, while $1 billion in convertible preferred…
Everpure and DigitalOcean face rising expectations as their stock prices shape Monday’s views.
Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…
Rubrik posted 38% Q2 revenue growth to $427.3 million, but Cloud ARR growth slowed to 39% and its enterprise value reached 15.7 times…
Nebius’s 1 GW annual active-capacity target from 2027 is realistic, according to a former product manager, with greenfield data centers…
Dell booked $131.7B of AI server orders in four quarters and held a $95B backlog as enterprise AI demand accelerates.
Jenga Global Master Fund returned 8.10% in Q3 2026, added Adobe and Mexican airports, and later initiated S&P Global.
Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.